Market Closed -
OTC Markets
11:21:34 2024-04-25 am EDT
|
5-day change
|
1st Jan Change
|
0.001
USD
|
-99.76%
|
|
-99.78%
|
-99.91%
|
Fiscal Period: December |
2021
|
2022
|
---|
Capitalization
1 |
148.1
|
6.58
|
Enterprise Value (EV)
1 |
146.8
|
39.33
|
P/E ratio
|
-1.68
x
|
-0.19
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
2.84
x
|
0.13
x
|
EV / Revenue
|
2.82
x
|
0.78
x
|
EV / EBITDA
|
-8.11
x
|
-1.35
x
|
EV / FCF
|
-7,198,359
x
|
-2,691,966
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
3.36
x
|
0.39
x
|
Nbr of stocks (in thousands)
|
1,441
|
1,473
|
Reference price
2 |
102.8
|
4.468
|
Announcement Date
|
3/23/22
|
3/22/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
26.01
|
37.77
|
52.1
|
50.29
|
EBITDA
1 |
-17.96
|
-7.489
|
-18.1
|
-29.19
|
EBIT
1 |
-19.64
|
-14.56
|
-28.72
|
-39.99
|
Operating Margin
|
-75.49%
|
-38.56%
|
-55.12%
|
-79.52%
|
Earnings before Tax (EBT)
1 |
-52.05
|
-18.4
|
-21.46
|
-34.1
|
Net income
1 |
-52.05
|
-18.26
|
-21.46
|
-34.11
|
Net margin
|
-200.08%
|
-48.36%
|
-41.2%
|
-67.83%
|
EPS
2 |
-1,155
|
-378.3
|
-61.22
|
-23.68
|
Free Cash Flow
|
-
|
-0.8456
|
-20.39
|
-14.61
|
FCF margin
|
-
|
-2.24%
|
-39.14%
|
-29.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/27/21
|
9/27/21
|
3/23/22
|
3/22/23
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
---|
Net sales
1 |
12.51
|
13.64
|
10.94
|
12.97
|
12.59
|
13.8
|
12.53
|
13.39
|
11.96
|
EBITDA
1 |
-2.589
|
-6.654
|
-10.3
|
-4.899
|
-5.841
|
-5.672
|
-6.525
|
-4.579
|
-3.819
|
EBIT
1 |
-6.14
|
-6.654
|
-10.3
|
-4.899
|
-10.51
|
-5.192
|
-10.31
|
-7.658
|
-6.096
|
Operating Margin
|
-49.1%
|
-48.77%
|
-94.19%
|
-37.78%
|
-83.48%
|
-37.61%
|
-82.26%
|
-57.19%
|
-50.95%
|
Earnings before Tax (EBT)
1 |
-3.225
|
10.82
|
-10.92
|
-5.613
|
-11.33
|
-6.234
|
-11.34
|
-8.642
|
-7.178
|
Net income
1 |
-3.225
|
10.81
|
-10.92
|
-5.613
|
-11.33
|
-6.234
|
-11.34
|
-8.681
|
-7.181
|
Net margin
|
-25.79%
|
79.21%
|
-99.91%
|
-43.29%
|
-90%
|
-45.16%
|
-90.51%
|
-64.83%
|
-60.02%
|
EPS
2 |
-2.240
|
7.500
|
-7.600
|
-4.000
|
-8.000
|
-4.000
|
-2.400
|
-1.000
|
-0.8100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/2/21
|
3/8/22
|
5/11/22
|
8/9/22
|
11/14/22
|
3/22/23
|
5/2/23
|
8/2/23
|
11/13/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
48.9
|
80
|
-
|
32.7
|
Net Cash position
1 |
-
|
-
|
1.33
|
-
|
Leverage (Debt/EBITDA)
|
-2.721
x
|
-10.68
x
|
-
|
-1.122
x
|
Free Cash Flow
|
-
|
-0.85
|
-20.4
|
-14.6
|
ROE (net income / shareholders' equity)
|
-
|
20%
|
78.8%
|
-111%
|
ROA (Net income/ Total Assets)
|
-
|
-13.1%
|
-17.3%
|
-27.2%
|
Assets
1 |
-
|
139.2
|
123.9
|
125.5
|
Book Value Per Share
2 |
-4,539
|
-3,720
|
30.60
|
11.50
|
Cash Flow per Share
2 |
601.0
|
291.0
|
28.20
|
4.660
|
Capex
1 |
0.22
|
0.45
|
0.58
|
0.07
|
Capex / Sales
|
0.86%
|
1.2%
|
1.12%
|
0.15%
|
Announcement Date
|
9/27/21
|
9/27/21
|
3/23/22
|
3/22/23
|
|
1st Jan change
|
Capi.
|
---|
| -99.91% | 8.88K | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|